Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ofloxacin + fluocinolone acetonide is a combination topical drug used primarily to treat **bacterial ear infections** and **skin infections** accompanied by significant inflammation and itching. **Ofloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and leading to bacterial cell death. **Fluocinolone acetonide** is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Together, this combination addresses infection and reduces inflammation for rapid symptom relief. It is most commonly supplied as ear drops or skin preparations for external use. The combination is typically marketed for otitis externa (outer ear infection), mixed microbial ear or skin infections, and conditions characterized by both infection and inflammation[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ofloxacin + fluocinolone acetonide.